

ANNUAL REPORT

2017

2018

DRIVING DISCOVERY

ADVANCING HEALTH

SERVING SOCIETY



ANNUAL REPORT

TABLE OF CONTENTS

4	MESSAGE FROM THE PRESIDENT
5	MEMBERSHIP AT A GLANCE
6	2017 ANNUAL MEETING
8	AJHG: SHARING DISCOVERY ACROSS HUMAN GENETICS
10	EDUCATION
12	POLICY AND ADVOCACY
14	FINANCIAL HIGHLIGHTS
16	SOCIETY LEADERSHIP, EDITORS, AND STAFF
1.8	PARTNERS AND DONORS



MESSAGE FROM THE PRESIDENT

Our community is driving new fundamental understanding of human genetics and delivering novel applications that influence every facet of life. Emerging uses range from preventive health to treating disease, tracing family ancestries, and understanding humanity's ancient origins. This knowledge is advancing society in countless ways—and also driving important questions on topics as diverse as privacy, law enforcement, equity, biomedical ethics, diversity and inclusion, and more.

As the world's largest community of human geneticists, the American Society of Human Genetics (ASHG) is dedicated to supporting this progress, addressing larger public policy issues, advancing public education and engagement, and supporting you: researchers and clinicians who are responsible for making and applying genetic discoveries and advances.

2017-2018 was eventful for the Society, with many achievements in longstanding valued programs. This Annual Report summarizes progress in each area of our mission, including ASHG's core scientific pillars to advance science and clinical applications – the Annual Meeting and *The American Journal of Human Genetics*. We'll also highlight other important activities, including successes in education and advocacy. Information about the Society's sound financial footing is also provided.

In service to this dynamic field, the Society is also in transition with new additions, some changes, and emerging possibilities. We have moved our headquarters to new office space and expanded our administrative independence; we welcomed a new AJHG editor in chief and a new ASHG executive director; completed the first member survey in some years; and have become more intentional in how we welcome and engage members into the life of the Society.

We've also initiated a strategic planning process. Our intent is to explore where our field is headed, the needs of members, and how ASHG may be best-positioned to help shape and support our community. Your input is essential to guide our thoughts as we prioritize programs that serve you, the field, and society most effectively. Therefore, the member survey and discussions at the Annual Meeting are vital, and we always benefit from your participation and feedback.

It has been a pleasure to be ASHG president. Thank you for this unexpected honor, which built on my wonderful experiences as a long-time ASHG member, AJHG editor, and volunteer. I am enthusiastic about ASHG's progress to date and its path ahead. That journey is rooted in our successes and experiences over 70 years, and thanks to our very strong present-day Board and committee leadership, I am confident that we will sustain the Society's impressive momentum.

We encourage you to join us as a member for 2019 — renewing your commitment to the field or perhaps joining us for the first time. Thank you!

Sincerely,

David L. Nelson, 2018 President

MEMBERSHIP AT A GLANCE



81 Countries



50 States




25%
Trainees



70%
Regular Members



MAJOR TYPE OF WORK



MEMBER ENGAGEMENT

91 Belong to a committee

360 Served as DNA Day essay judges

Reviewed 2018 meeting abstracts

ASHG ANNUAL REPORT MESSAGE FROM THE PRESIDENT MEMBERSHIP AT A GLANCE ASHG ANNUAL REPORT



2017 ANNUAL MEETING GENERATES GREAT SCIENCE & NETWORKING

The ASHG 2017 Annual Meeting in Orlando was a high point of the Society's work to advance scientific knowledge through learning, debate, and networking. In total, ASHG received more than 3,100 abstracts in 2017 and welcomed nearly 7,500 attendees and more than 220 exhibiting companies. Early indications suggest an even more vibrant meeting in San Diego in 2018.



SHARING DISCOVERIES. SHAPING OUR FUTURE.


The 2017 meeting featured 12 high scoring abstracts in plenary sessions on topics such as gene expression, genetic factors

associated with autism, and risk factors for breast cancer and melanoma; 360 platform sessions representing the meeting's cross-cutting science and diversity of topics; as well as 17 invited sessions organized through a competitive submission process on topics such as human brain evolution, single-cell genomics, complex traits, diversity in genomics research. Other highlights included the widely attended "Building Bridges" session with the European Society of Human Genetics, a joint symposium with the World Congress of Psychiatric Genetics on the genetics of neurodevelopmental disorders and other sessions that addressed genetics policy, communications training and education strategies. ASHG's Training and Development Committee also led a range of well received programming targeted to serve ASHG's earliest-career members.









The 2017 Presidential Symposium was especially engaging. President Nancy Cox welcomed Bill Gates, Chairman of the Bill & Melinda Gates Foundation, and NIH Director Francis Collins for a session exploring global health and its intersection with human genetics. Nancy, Bill, and Francis were joined by 2017 Program Committee Chair Peter Scacheri to discuss progress and challenges in applying growing genetic knowledge to address problems affecting millions around the globe. The event remains online for the community and public to watch.

As Nancy relayed in her opening remarks, "For decades, these two remarkable people have blazed new trails in science and technology.

And through their own professional lives and personal passions, they have both been deeply committed to advancing science and serving society. Together, we'll discuss how new scientific understanding could transform how we approach infectious disease and genetic contributors to global health disparities and outcomes."

ASHG works hard each year to maintain the meeting's tremendous value to the field, as well as innovate to serve attendees even better. The meeting garnered strong satisfaction ratings from attendees, who also suggested areas for further development. While recognizing the meeting is fundamentally sound and successful, the Board tasked an ad hoc review group to explore how the Society could continue to enhance the meeting. The discussion included adding new ways to increase engagement and networking, which will be a focus in 2018 and beyond. Other new features in 2018 include an advocacy session as well as innovative "inspiration lounges," where attendees can talk informally with speakers before or after major talks, encouraging dialogue, interaction between generations, and learning opportunities.

ASHG ANNUAL REPORT 2017 ANNUAL MEETING ASHG ANNUAL REPORT 7

AJHG: SHARING DISCOVERY ACROSS HUMAN GENETICS


The American Journal of Human Genetics is one of the field's leading journals. Known for its scientific excellence and rigor as well as swift time to decision, The Journal will enter 2019, its 70th year, with an exceptional reputation for scientific quality, breadth, and field leadership. Through its broad reach and impact, AJHG remains very well-positioned to chronicle—and help shape—the continued evolution of human genetics.

December 2017 was a time to say thank you and farewell to the long successful editorial leadership of David Nelson, and the ASHG Board of Directors thanked him for his service. In addition to his stewardship of the scientific content, one of David's notable passions—the rich history of the human genetics and the Society itself—was a hallmark of the AJHG covers during his tenure. He also highlighted that history in his final reflection as editor, in which he observed the many changes and progress points in the field over the last 65+ years and wondered what the next decades might hold.

January 2018 thus also saw the arrival of a new editor-in-chief: Bruce Korf. In an editorial, Bruce introduced himself and observed that The Journal possesses the unique ability "to grow along with one of the most rapidly evolving areas of scientific endeavor." He further noted that he hoped to reinforce The Journal as broadly based, covering the full range of field content." The commitment of The Journal to publish the best scientific research in human genetics, including population genetics, statistical genetics, molecular genetics,



BRUCE KORF. MD. PHD EDITOR-IN-CHIEF, AJHG



THROUGH 2017, AJHG COVERS FEATURED THE PRESIDENTS OF ASHG TO HIGHLIGHT THE HISTORY OF THE FIELD AND SOCIETY. genomics and gene discovery, and yes, clinical and translational studies, remains undiminished," he noted. At the same time, he also made the case for papers to explore diagnostic approaches and reports on preclinical studies of potential treatments, clinical trials, cancer genetics, and even topics for policy debate and discussion.

Even with its continuing high regard as a scientific leader, The Journal is innovating to keep pace with changing needs in the field and forces in the scientific publishing environment. New types of content, including new feature content as well as a broad range of papers, will reinforce that innovation. In years to come, it will continue to evolve and serve the field successfully.


MOST CITED ARTICLES, 2017		
ARTICLE TITLE	CITATIONS IN 2017	
DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-analysis	74	
The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities	62	
Genotype Imputation with Millions of Reference Samples	44	
Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma	42	
Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents	39	
The Genetic History of African Americans, Latinos, and European Americans across the United States	37	

AJHG: SHARING DISCOVERY ACROSS HUMAN GENETICS

EDUCATION: ENGAGING STUDENTS & THE PUBLIC, SUPPORTING HUMAN GENETICS PROFESSIONALS

Educating the diverse human genetics community, supporting trainees, and engaging students and the public are at the heart of ASHG's mission. In 2017 and 2018, the Society led many successful programs serving high school students, undergraduate students, and the larger public. It also began to explore how to best leverage its strengths to increase professional education for members.

ASHG's longest-standing, widest-reaching public education program is the DNA Day Essay Contest, which garnered extraordinary global engagement in 2018. Open to students in grades 9-12 worldwide, participants write a 750-word essay through which they examine, question, and reflect on important genetics concepts. Teachers play a central role in essay submission, and in many cases incorporate the contest into their curriculum. The 2018 contest prompted more than 1,000 submissions from students in 43 U.S. states and 23 countries. Following review by more than 300 dedicated ASHG members, outstanding essays from writers in New York, Los Angeles, and Kyiv, Ukraine were chosen. Additionally, ASHG is taking steps to increase its participation in the "DNA Day Campaign," under the leadership of the National Human Genome Research Institute, and led the successful annual workshop focused on enhancing teaching strategies for undergraduate educators.



THE 2018 DNA DAY ESSAY CONTEST RECEIVED OVER 1,000 ENTRIES FROM HIGH SCHOOL STUDENTS WORLDWIDE.

The Genomic Medicine Education Consortium. a multi-year effort of the Society, wrapped up in 2018 as an effective endeavor to explore strategies for educating non-genetics health professionals. With support from valued partners (see donors and sponsors section), the program made meaningful inroads to understand the complex challenge of improving genetic knowledge among non-genetics specialists, with content addressing pediatricians, oncologists, speech-language professionals, and others. While the Board elected to end the consortium in order to explore other emerging educational priorities, the initiative's resources will remain available on the website and through several project partners.

In the Society's effort to serve members effectively, ASHG's programs for trainees and the broader field gained traction this year. In partnership with The Jackson Laboratory, ASHG is in its second year of organizing "Conference to Career," a year-long program for as many as 130 trainees. Through a combination of in-person and online sessions, the program helps them make the most of the ASHG Annual Meeting to spark career directions. The Society also enabled nine trainees from underrepresented backgrounds to attend the ASHG Annual Meeting and hosted the trainee diversity breakfast. These activities reinforce the importance of diversity and inclusion to advance human genetics and help trainees network with one another and within the broader Society.

ASHG was also pleased to expand professional education, including a widely attended webinar with AJHG on the Matchmaker Exchange and new planned events with the National Society of Genetic Counselors to support professional development for counselors in research.







POLICY AND ADVOCACY: ADVANCING HUMAN GENETICS IN THE PUBLIC ARENA

ASHG is committed to building greater public support for human genetics and to advocating for policies that advance and protect genetic research. Over the last two years, the Society has been building its policy and advocacy impact in Washington and will be enhancing its voice on issues that affect our field and larger society. In summer 2018, ASHG launched its advocate's pledge to empower members to get involved in advocacy activities.

In the past year, ASHG has taken the lead celebrating an important policy milestone: 10 years of U.S. federal protections against genetic discrimination, a top priority for the Society. Specifically, the month of May marked 10 years since the signing into law of "GINA"—the Genetic Information Nondiscrimination Act. The anniversary sparked many ASHG activities, including a new video to explain the law's value for the public. The Society also spoke to the importance of diversity in genetic research, as illustrated in a February 2018 Orlando Sentinel op-ed by Past President Nancy Cox. ASHG led an international group of 11 organizations that issued a major statement on germline genome editing that garnered broad visibility. Other top policy priorities include funding for genetics research, the return of results to research participants, issues related to genetic testing, the interface of genomics research and genomic medicine, protecting genetic privacy, the teaching of evolution, and the genetics of race and ancestry.

ASHG POSITION STATEMENT

Human Germline Genome Editing

Kelly E. Ormond, ^{1,19,4} Douglas P. Mortlock, ^{2,19} Derek T. Scholes, ^{3,19} Yvonne Bombard, ⁴ Lawrence C. Brody, ⁵ W. Andrew Faucett, ^{6,7} Nanibaa' A. Garrison, ^{6,9} Laura Hercher, ^{7,10} Rosario Isasi, ¹¹ Anna Middleton, ^{12,13} Kiran Musunuru, ¹⁴ Daniel Shriner, ^{15,16} Alice Virani, ^{17,18} and Caroline E. Young⁸

With CRSFR/Cas9 and other genome-editing technologies, successful somatic and germline genome editing are becoming feasible. To expond, an American Society of Human Genetics (SAFIO) workgroup developed this position statement, which was approved by the ASHG Board in March 2017. The workgroup included representatives from the UK Association of Genetic Counselors. Andian Association of Genetic Counselors. Increasing the Counselors and Counselors are groups, as well as the American Society for Reproductive Medicine, Asia Pacific Society of Human Genetics, British Society for Reproductive Medicine, Asia Pacific Society of Human Genetics, British Society for Genetic Medicine, Human Genetics, endorsed the final statement. The statement includes the following positions; I) At this time, given the nature and number of unanswered scientific, chical, and policy questions, it is in appropriate to perform germline gene editing that cultimates in human pregnancy. (2) Currently, there is no reason to prohibit in vitro germline genome editing on human embryos and gametes, with appropriate to versight and consent from donous, to Galitate research on the possible future clinical applications of gene editing. There should be no prohibition on making public funds available to support this research. (3) Future clinical application of human germline enome editing the advanced unless at a minimum, there is it a commelline medical rationale, (b) an evidence base that supports genome editing should not proceed unless, at a minimum, there is (a) a compelling medical rationale, (b) an evidence base that s its clinical use, (c) an ethical justification, and (d) a transparent public process to solicit and incorporate stakeholder input.

The American Society of Human Genetics (ASHG) Workthe ASHG Board of Directors in March 2017

Introduction
The American Society of Human Genetics (ASHG) Workgroup on Human Germline Genome Editing developed
the present position statement and explanatory paper
between August 2015 and January 2017. This group,
composed of a combination of basic and clinical scientists,
bioethicists, health services researchers, lawyers, and genetic counselors, worked together to integrate the scientific status of and socio-ethical views toward human germline genome editing (defined as using genome-editing
techniques in a human germ cell or embryo) into this
statement. The group met regularly through a series of
weekly conference calls and email discussions, proposed
a draft statement to the ASHG Board of Directors in April
2016, presented the draft policy statement to ASHG and
European Society of Human Genetics (ESHG) members at
the ASHG-ESHG Building Bridges session in May 2016,
and requested comments from ASHG members in June
2016. A total of 27 comments were received, 4 of which
were in opposition to the statement. All comments and
the composition to the statement. All comments and
services of the comments and the comments and the ASHG-ESHG Building Bridges session in May 2016,
and requested comments from ASHG members in june
2016. A total of 27 comments were received, 4 of which
were in opposition to the statement. All comments and
services of the comments and were in opposition to the statement. All comments and sight or strong institutional review boards [IRBs], the po-recommended modifications were reviewed by the com-

THE SOCIETY'S STATEMENT ON GERMLINE GENOME EDITING GARNERED BROAD VISIBILITY.

ASHG is also committed to supporting the scientific enterprise directly, as well as by joining forces with others to protect the vital role of science in society.

On the positive side, bipartisan Congressional support for medical research remains very strong, and ASHG is actively engaged with the broader advocacy community to push for sustained, robust increases in federal research funding. The final 2018 budget included a remarkable \$3 billion increase for NIH and 2019 negotiations featured sustained support for strong increases. This success reflects the impact



THE ASHG/NHGRI GENETICS & PUBLIC POLICY FELLOWSHIP PROVIDES GENETICISTS AN OPPORTUNITY TO CONTRIBUTE TO THE POLICYMAKING PROCESS.

of the united advocacy community in Washington that has worked over a decade to make the case that research improves health, advances knowledge, and strengthens economies.

Conversely, ASHG has been deeply concerned and active when it comes to actions that run counter to the Society's fundamental values. Following the announcement of the U.S. administration's travel ban, the Society announced its opposition strongly and clearly. We continue to monitor other issues of concern including challenges to the teaching of evolution, the misuse of genetics to

advance racial supremacy, and challenges to reproductive freedom.

Throughout, ASHG is increasingly engaged with the broader research advocacy community. This includes new membership in Research!America, a premier medical research advocacy organization, continued membership in the Federation of American Societies for Experimental Biology, and closer communication with the American Association for the Advancement of Science.

POLICY AND ADVOCACY ASHG ANNUAL REPORT ASHG ANNUAL REPORT POLICY AND ADVOCACY

FINANCIAL HIGHLIGHTS

ASHG's financial health remains sound, with prudent management strategies that protect the Society and advance its goals. Moreover, thanks to long-time careful financial stewardship, ASHG has the capacity to look forward and begin planning for future investments that serve members, the Society, and the field.

CY2017 PERFORMANCE

Although ASHG has maintained net revenue surpluses over many years, 2017 presented a set of one-year challenges that resulted in a net operating loss of approximately \$354,000. Reduced revenue resulted primarily from lower-than-budgeted exhibit and registration revenue for the 2017 Annual Meeting, while expenses were higher than budgeted, due primarily to technology investments and the transition of the Society's executive staff position. Thanks to dedicated Board stewardship of the reserve over many years, the Society was able to absorb this one-year shortfall and the FY2019 budget anticipates a return to positive financial performance. ASHG's reserve fund was able to capitalize on strong financial markets, ending the June 30, 2018 period with a value totaling \$17,839,428.

CY2017 revenue and expenses were as follows. ASHG's CY2017 Audited Financial Statements are available online.





PRUDENT MANAGEMENT

The Society has also updated its financial management and systems to help it most effectively support Society operations and deploy resources, including changing its fiscal year from a calendar year to a July-June period. The transition will produce a single "short-year FY2018" (January-June 2018) that reflects only six months of revenue and expense. Beginning July 1, 2018, future fiscal years will again reflect full 12-month periods on the new cycle. Additionally, after many years of flat pricing for the Annual Meeting and membership, ASHG is modestly increasing rates to address inflation. In making these choices, the Society committed to reinforce the benefits of membership, including a decision to maintain the substantial member discount for Annual Meeting registration, which more than covers the cost of membership.

LOOKING FORWARD

Finally, the Society enabled limited, responsible deployment of reserves for highest-priority investments that advance the Society and the field. The Board authorized a limited use in January 2018, including sustained support for technology and infrastructure upgrades. That investment will help the Society grow, increase vital data security and integrity, and better serve members' growing technology expectations. Funds were also invested in a move to new offices in May 2018, following the end of ASHG's long-time lease on the campus of the Federation of American Societies for Experimental Biology.

Finally, the Board is also making additional investments in the future, including support for strategic planning. This began by making resources available to better understand the Society's membership composition and needs through the first member survey in some years and will continue with input from a range of stakeholders. Combined, this will help the Board prepare for a thoughtful strategic planning dialogue early in 2019. The goal will be to help chart the Society's next five years of growth, building on the solid foundation created by members and leaders over ASHG's 70 years of distinction and achievement.

ASHG ANNUAL REPORT FINANCIAL STABILITY ASHG ANNUAL REPORT 1

2018 SOCIETY LEADERSHIP, EDITORS, AND STAFF

The American Society of Human Genetics gratefully recognizes the dedication of its volunteers, editors, and staff. The Society could not serve the field so effectively without your engagement and expertise. Thank you!

BOARD OF DIRECTORS

Officers

David L. Nelson, PhD President

Nancy J. Cox, PhD Past President

Leslie G. Biesecker, MD Incoming President

Gail P. Jarvik, MD, PhD

Secretary

Geoffrey M. Duyk, MD, PhD

Treasurer

Bruce D. Gelb, MD Incoming Treasurer

Directors

Katrina A.B. Goddard, PhD

Neil A. Hanchard, MBBS (Hons.), DPhil

Nicholas Katsanis, PhD

Donna M. Martin, MD, PhD

Zachary S. Nevin, PhD

Sharon Plon, MD, PhD

Charles N. Rotimi, PhD

Susan A. Slaugenhaupt, PhD

Nancy B. Spinner, PhD

Sarah A. Tishkoff, PhD

Ex officio

Mona V. Miller Executive Director

COMMITTEE CHAIRS

Fowzan Alkuraya, MD Awards Committee

Kathryn Garber, PhD Communications Committee

Geoffrey M. Duyk, MD, PhD Finance Committee

Jannine Cody, PhD

Information and Education Committee

Kay E. Davies, PhD Nominating Committee

Heather Mefford, MD, PhD Program Committee

Jennifer K. Wagner, PhD, JD Social Issues Committee

Lauren C. Tindale, BS/BA
Training and Development Committee

THE AMERICAN JOURNAL OF HUMAN GENETICS

Bruce Korf, MD, PhD, Editor in Chief Sara B. Cullinan, PhD, Deputy Editor

Sarah Ratzel, PhD, Science Editor

Lauren Hicks, Editorial Assistant

Associate Editors

Michael Bamshad, MD

Stephen J. Chanock, MD

Stacey Edwards, PhD

Jozef Gecz, PhD

Gail P. Jarvik, MD, PhD

Jonathan Marchini, DPhil

Stephen Montgomery, PhD

Lucy Osborne, PhD

Bogdan Pasaniuc, PhD

Sharon Plon, MD, PhD

Anita Rauch, MD

Michael Talkowski, PhD

ASHG STAFF

Executive Office

Mona V. Miller, Executive Director

Mary Rose Rivera, Governance and Administration Manager

Ndidi Ahaghotu, Office Assistant/Receptionist

Communications and Marketing

Nalini Padmanabhan, Director

William Anderson, Designer

Ann Klinck, Communications and Marketing Assistant

Education and Membership

Kelly Ventura, Senior Director

Kanika Pulliam, PhD, Senior Manager, Education &

Career Development Programs

Evelyn Mantegani, Public Education & Engagement

Specialist

Erin Königsdörffer. Education Assistant

Teresa Ramirez, Genetics and Education Fellow (2016-2017)

Dyanna Christopher, Genetics Education and Engagement Fellow (2018-2019)

Finance and Operations

Frank Balser, Senior Director

Yimang Chen, Senior Manager, Information Technology and Data

Guangrong (Kevin) Ma, Web Developer

Colin Djieugoue, Manager, Accounting and Budget

Meetings and Exhibits

Pauline Minhinnett, Senior Director

Carrie Morin, Senior Manager, Exhibits and Sponsorship

Emily Greene, Meetings Program Manager

Peggi McGovern, Meetings & Exhibits Coordinator

Amanda Olsen, Meetings Assistant

Public Policy and Advocacy

Derek Scholes, PhD, Senior Director

Jillian Galloway, Science Policy Analyst

Christa Wagner, PhD, Genetics and Public Policy Fellow (2016-2017)

Nikki Meadows, PhD, Genetics and Public Policy Fellow (2017-2018)

Eve Granatosky, PhD, Genetics and Public Policy Fellow (2018-2019)

As this report spans the years 2017-2018, a number of the activities began under the leadership of former Executive Director Joseph McInerney, who retired in July 2017. The Society recognizes and thanks Joe for his extraordinary service to the Society and his career-long dedication to advancing the field of human genetics.

2017-18 PARTNERS AND DONORS

Progress in human genetics will advance only through the active contributions and cooperation of many actors - researchers and clinicians, institutions, individuals private sector companies, federal agencies, advocacy partners, and fellow international organizations. We acknowledge and thank our program partners and donors for your support and active collaboration in 2018.





































ASHG is grateful for the generosity of the individual donors listed below.

Hisama Fuki

Hong, Yeon

Howell, R.

Howard, Alicia

Meng, Yan

ASHG is grateful to	r the generosity of t
Abou Jamra, Rami	Dev, Vaithilingam
Abramson, Ruth	Devaney, Joseph
Alburo, Anthony	Dey, Kushal
Almeida, Jose Carlos	Dilorenzo, Ann
Alodaib, Ali	Disteche, Christine
Amster, Ruth	Dobyns, William
Arbour, Laura	Donahue, Roger
Aschard, Hugues	Downey, Colin
Ashutosh, Ashutosh	Dumont-Driscoll, Marilyn
Bader, Ingrid	Dunston, Georgia
Bailey, Mark	Eddleman, Keith
Bailey-Wilson, Joan	Eggerding, Faye
Bamforth, John	Elespuru, Rosalie
Ban, Hao	Eppig, Janan
Barcellos, Lisa	Erbe, Richard
Bargawi, Hind	Estabrooks, Laurel
Barrantes, Ramiro	Fakhro, Khalid
Bartholomew, Dennis	Falk, Rena
Batista, Oriana	Falk, Dorian
Beck, Anita	Farber, Charles
Bellus, Gary	Felice, Alex
Biesecker, Leslie	Fellman, Lynn
Bixenman, Helen	Fellous, Marc
Black, Susan	Flax, Judy
Bressac-de Paillerets, Brigitte	Fortina, Paolo Frengen, Eirik
Bromberek, Sarah	Garnica, Adolfo
Brown, Judith	Gatti, Richard
Buchanan, Philip	Geraedts, Joseph
Bult, Carol	Giannikou, Krinio
Carlo, Simon	Giovannucci Uzielli, Maria
Castronovo, Chiara	Goldstein, Alisa
Child, Anne	Gonzalez, Iris
Chioza, Barry	Gottesman, Gary
Chitayat, David	Grass, Frank
Choquet, Karine	Grogan, James
Choy, Yew	Guo, Chao
Clendenning, Mark	Hajianpour, M.J.
Cobben, Hans	Harris, David
Corsaro, Cheryl	Harris, James
Cubells, Joseph	Hassold, Terry
Darlow, John	Hauser, Elizabeth
Davalos, Jorge	Hegele, Robert
Deardorff, Matthew	Herms, Stefan
Deguchi, Kimiko	Hill, Gene
D D :	, Garia

Hu, Xiaofeng Mira, Marcelo Hung, Christina Moedjono, Sri Mora, Lina Ihnen, Jeffrey Immken, LaDonna Murakami, Akira Inhorn, Stanley Murray, Jeffrey Inoue, Ken Nath, Swapan Igbal, M. Anwar Naumova, Anna Jackson, Laird Nelson, David Jackson, Christine Neri, Joao Jacky, Peter Nickkholgh, Bita Jorde, Lynn Nielsen, Jonas Kammerer, Candace Numabe, Hironao Karolak, Justyna Nussbaum, Robert Kastner, Daniel Olmos Morfín, Dorian Karitina Kastury, Rama Orkunoglu-Suer, Funda Kelly, Charles Ostrer, Harry Kelly, Jane Ozes Ak, Burcak Kennaway, Nancy Panny, Susan Kin, Yoshiaki Parham, Peter Kinoshita, Akira Pasion, Sally Knowles, Barbara Pasquali, Marzia Konecki, David Pasztor, Linda Kopera, Aimon Patil, Shivanand Korenberg, Julie Peters, June Kumar, Chitra Phelan, Katy Lalande, Marc Preuss, Christoph Laurie, Cathy Priest, Jean Leppig, Kathleen Punj, Sumit Leroy, Jules Qian, Yaping Lose, Edward Raymond, Gerald Lovaton Espadin, Rolando Razaz, Parisa Lustig, Arthur Rogers, John Luthardt, Frederick Roubertoux, Pierre Lynch, Thomas Russell, Laura Macri, Charles Rybicki, Benjamin Malkin, David Sanchez Russo, Rossana Manace, Leslie Sanford-Biggerstaff, Julie Mardach, Rebecca Sanghavi, Kunal Marion, Robert Santibanez-Koref, M. Martinez, Jose Schafer, Irwin Martinez de Villarreal, Laura Schanfield, Moses Matharu, Navneet Scheuner, Maren Matthews, Anne Schirripa, Osvaldo McBride, Kim Schneider, Adele McCormack, Michael Schnur, Rhonda McDaniel, D. Seguin-Spillman, Lana McGillivray, Barbara Sen, Askin Mendelsohn, Nancy

Shaw, Marlene

Sherman, Stephanie

Sheth, Jayesh

Shih, Ling-Yu

Shin, Dong-Jik

Shinde, Deepali

Slatkin, Montgomery

Singh, Rama

Sloan, Jennifer

Smith, Moyra

Smith, Janice

Sofer, Tamar

Sorant, Alexa

Sosonkina, Nadiya

Stankiewicz, Pawel

Streeten, Elizabeth

Spinner, Nancy

Strong, Louise

Sybert, Virginia

Tayebi, Nahid

Temple, Gary

Turocy, John

Ulloa, Janella

Uribe, Daniel

Walker, Ann

Weinreb, Neal

Wiggs, Janey

Wilch, Ellen

Wiley, John

Williams, Robert

Williamson, Roger

Willing, Marcia

Withers, Doris

Wu, Jer-Yuarn

Xiang, Bixia

Yanjun, Jiang

Young, Terry-Lynn

Younkin, Steven

Zang, Klaus

Zito, Antonino

Zurcher, Vickie

Ye, Jun

Wyandt, Herman

Yamagata, Zentaro

Yamaguchi, Masatoshi

Tiirikainen, Maarit

Vandenberghe, Antoon

Wegman-Ostrosky, Talia

Watanabe, Richard

ASHG ANNUAL REPORT DONORS AND PARTNERS DONORS AND PARTNERS ASHG ANNUAL REPORT

Deka, Ranjan

Delozier, Dawn

Dessein, Alain

Demarchi, Mario



6120 Executive Blvd, Suite 500 Rockville, Maryland 20852 www.ashg.org